Press Releases

26.04.19 2018 Annual Report
11.04.19 Preliminary Results for the Year Ended 31 December 2018
29.03.19 hVIVO & Imutex Limited to Present at IVW 2019
08.03.19 Notice of Preliminary Results 2018
10.01.19 Positive Data for Phase IIb FLU-v Challenge Study
31.10.18 AGS-v Partial Preliminary Results
08.10.18 Two New Contracts for RSV Human Challenge Studies
08.10.18 Directorate Change
20.09.18 Interim Results
18.06.18 hVIVO Reports Positive Results from the Phase IIb Field Study of FLU-v (FLU-v 003)
23.05.18 Result of AGM
27.04.18 Posting of 2017 Annual Report and Financial Statements
19.04.18 Audited 2017 Preliminary Results
19.04.18 Chief Executive Officer Steps Down
10.04.18 Statement regarding share price
06.04.18 Notice of Preliminary Results
26.03.18 Initial results from Imutex’s Phase IIb study of FLU-v
30.10.17 Directorate Change
21.09.17 Half-year Financial Report
20.06.17 Board Change
24.05.17 Results of AGM
28.04.17 Posting of 2016 Annual Report and Financial Statements
20.04.17 Audited 2016 Preliminary Results
13.04.17 Trading Update
21.02.17 hVIVO notes the initiation of a Phase I clinical trial with AGS-v
09.02.17 Data from PrEP Biopharm’s two Phase IIa clinical studies
30.12.16 Change of auditor
22.09.16 Half-year Financial Report
21.09.16 Trading update
02.09.16 hVIVO Landmark Asthma Study Underway
14.06.16 Favourable results for PrEP Biopharm’s Flu Study
24.05.16 David Norwood Lock-in Deed
23.05.16 Result of AGM
28.04.16 Posting of 2015 Annual Report and Financial Statements
25.04.16 Initial results for PrEP Biopharm’s PrEP-001 Phase IIa Flu Study
22.04.16 Joint Venture Investment with the SEEK Group
20.04.16 Board Changes
20.04.16 Audited 2015 Preliminary Results
15.12.15 Result of General Meeting
26.11.15 Conditional Placing to raise £20.5 million
02.11.15 hVIVO invests in PrEP Biopharm Limited
02.11.15 Trading Update
24.09.15 Half Yearly Report
26.05.15 Result of AGM
24.04.15 Posting of 2014 Annual Report and Financial Statements
16.04.15 Audited 2014 Preliminary Results
16.04.15 Confirmation of change of name to hVIVO plc
13.04.15 Change of Name to hVIVO
16.02.15 Trading Update
25.11.14 Trading Update
07.10.14 Board change
25.09.14 Half Yearly Report
01.09.14 Result of General Meeting
21.08.14 hVIVO HCM of GS-5086 in RSV for Gilead Sciences
14.08.14 Conditional Placing to raise £33.6 million
28.07.14 hVIVO HCM study of AL-8176 in RSV for Alios BioPharma
14.07.14 Board change
26.06.14 Board change
12.06.14 Board changes
04.06.14 Start of hVIVO challenge study in asthma
02.06.14 Investor Event
21.05.14 Result of AGM
17.04.14 Posting of 2013 Annual Report and Accounts
09.04.14 Board Changes
09.04.14 Audited 2013 Preliminary Results
19.03.14 New state of the art biomedical facility in UK
04.03.14 Acquisition
16.12.13 Trading Update
26.09.13 Half Yearly Report
28.08.13 Contract Win
23.08.13 Contract Win
02.07.13 Result of General Meeting
01.07.13 Contract Win
14.06.13 Conditional Placing to raise £25.5 million
19.04.13 Posting of 2012 Annual Report and Accounts
10.04.13 Audited 2012 Preliminary Results
07.01.13 Contract Win
12.12.12 Trading Update
22.10.12 Contract Win
24.09.12 Half Yearly Report
10.05.12 Contract Win
03.05.12 First day of Dealings and Admission to AIM